ADC Therapeutics SA (NYSE:ADCT) reported its third-quarter 2026 financial results on November 9, 2026, disclosing net product revenues of $21.0 million and cash and cash equivalents of $189.2 million as of September 30, 2026, alongside details of a strategic financial restructuring completed in October 2026.

Key Highlights

  • Net product revenues: $21.0 million for Q3 2026, up from $15.8 million in Q3 2025, with the increase primarily attributed to volume growth, according to the filing.
  • Cash position: $189.2 million in cash and cash equivalents as of September 30, 2026, compared to $261.3 million as of December 31, 2025.
  • PIPE financing: An $86.6 million private investment in public equity was completed in October 2026, with participation from Bain Capital Life Sciences, Redmile, TCGX, and Nantahala Capital; approximately 12.9 million common shares and 48 million warrants with a strike price of CHF 0.08 were issued.
  • Debt restructuring: The senior secured loan agreement was amended to reduce outstanding principal by $68.5 million to $50 million, eliminate scheduled principal amortization, and remove the minimum liquidity covenant.
  • Net loss narrowed: GAAP net loss for Q3 2026 was $25.3 million, or $0.16 per basic and diluted share, versus $41.0 million, or $0.30 per share, in Q3 2025.
  • Japan regulatory progress: Tanabe Pharma Corporation submitted a marketing authorization application for ZYNLONTA in Japan, and entered into an exclusive sublicensing agreement with Nippon Shinyaku Co., Ltd., for commercialization in Japan.
  • Expected cash runway: The company disclosed an expected cash runway extending into 2029 following the restructuring transactions.

ADC Therapeutics Reports Q3 2026 Financials and October Restructuring Details

According to the filing, ADC Therapeutics reported net product revenues of $21.0 million for the third quarter ended September 30, 2026, and $59.7 million for the nine months ended September 30, 2026, compared to $15.8 million and $51.2 million for the same periods in 2025. The company attributed the increase primarily to higher sales volumes. License revenues and royalties were $0.7 million for Q3 2026, unchanged from Q3 2025, while the nine-month figure declined to $2.1 million from $7.1 million in 2025, with the year-over-year decrease attributed to a prior-year milestone payment from a partner.

Total GAAP operating expenses fell to $36.1 million in Q3 2026 from $47.4 million in Q3 2025, a reduction the filing characterized as 24% quarter-over-quarter, driven primarily by lower research and development expenses. R&D expense for the quarter was $14.7 million, down from $26.8 million in the same period of 2025. The company reported that non-GAAP adjusted total operating expenses were $32.1 million for Q3 2026, compared to $45.0 million for Q3 2025, a reduction the filing stated as 29%. The GAAP net loss per basic and diluted share improved to $0.16 in Q3 2026 from $0.30 in Q3 2025.

The filing disclosed that in October 2026, the company completed a comprehensive financial restructuring. The $86.6 million PIPE included new investor Bain Capital Life Sciences alongside existing investors. The HealthCare Royalty financing agreement was amended to eliminate a $150 million change-of-control payment. The senior secured loan agreement was amended to reduce outstanding principal by $68.5 million to $50 million, eliminate scheduled principal amortization, and remove the minimum liquidity covenant. The company stated these actions extend its expected cash runway into 2029. Additionally, five oral presentations covering ZYNLONTA clinical data, including Phase 1b LOTIS-7 and Phase 3 LOTIS-5 results, were accepted for the 68th ASH Annual Meeting in December.

What Was Disclosed

ADC Therapeutics filed its Q3 2026 financial results, reporting $21.0 million in net product revenues, $189.2 million in cash, a narrowed GAAP net loss of $25.3 million, and details of an October 2026 restructuring including an $86.6 million PIPE and senior loan reduction of $68.5 million, extending expected cash runway into 2029.